Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 387 | 0.82 |
| pathways Reactome | 2 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 10022
Sealed predictions
- ACSS2 in dopamine neurons, braak-0.20 (p 0.613) → -0.81 (p 0.008)receipt 10030
Swarm cases
receipt 10030: ACSS2 in dopamine neurons, braak
- power
- full sample -0.41 (p 0.087, n 18), 95% CI -0.74 to +0.07. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.39 (p 0.107, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.107, n 18). could be the mix.
- skeptic
- leave-one-out range -0.59 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.087, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACSS2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts